Analysts Set IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Price Target at $46.60

by · The Markets Daily

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Free Report) have received an average rating of “Moderate Buy” from the seventeen ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and fifteen have issued a buy rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $46.60.

Several equities research analysts have recently commented on the company. Mizuho upped their target price on IDEAYA Biosciences from $44.00 to $46.00 and gave the company an “outperform” rating in a report on Tuesday, November 11th. Weiss Ratings restated a “sell (d-)” rating on shares of IDEAYA Biosciences in a report on Thursday, January 22nd. JPMorgan Chase & Co. raised their target price on shares of IDEAYA Biosciences from $74.00 to $79.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Wall Street Zen upgraded shares of IDEAYA Biosciences from a “hold” rating to a “buy” rating in a report on Sunday, November 9th. Finally, Royal Bank Of Canada upped their price target on shares of IDEAYA Biosciences from $41.00 to $45.00 and gave the company an “outperform” rating in a research report on Wednesday, January 21st.

Check Out Our Latest Report on IDEAYA Biosciences

IDEAYA Biosciences Stock Performance

IDEAYA Biosciences stock opened at $32.99 on Tuesday. The firm has a market cap of $2.89 billion, a price-to-earnings ratio of -17.74 and a beta of 0.05. IDEAYA Biosciences has a 1 year low of $13.45 and a 1 year high of $39.28. The firm’s 50 day moving average price is $35.04 and its two-hundred day moving average price is $29.55.

IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $1.33 EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $1.45. The company had revenue of $207.83 million for the quarter, compared to analyst estimates of $59.98 million. As a group, equities analysts predict that IDEAYA Biosciences will post -3.07 EPS for the current fiscal year.

Institutional Trading of IDEAYA Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of the business. Arizona State Retirement System raised its position in IDEAYA Biosciences by 1.5% during the third quarter. Arizona State Retirement System now owns 23,324 shares of the company’s stock valued at $635,000 after buying an additional 353 shares during the period. Daiwa Securities Group Inc. boosted its position in IDEAYA Biosciences by 16.1% during the 2nd quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock worth $66,000 after acquiring an additional 436 shares during the period. PNC Financial Services Group Inc. grew its stake in IDEAYA Biosciences by 16.1% during the 3rd quarter. PNC Financial Services Group Inc. now owns 3,881 shares of the company’s stock valued at $106,000 after acquiring an additional 537 shares in the last quarter. Farther Finance Advisors LLC grew its stake in IDEAYA Biosciences by 171.1% during the 4th quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock valued at $32,000 after acquiring an additional 580 shares in the last quarter. Finally, Comerica Bank increased its holdings in shares of IDEAYA Biosciences by 36.5% in the 4th quarter. Comerica Bank now owns 2,514 shares of the company’s stock valued at $87,000 after purchasing an additional 672 shares during the period. Institutional investors and hedge funds own 98.29% of the company’s stock.

About IDEAYA Biosciences

(Get Free Report)

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.

Recommended Stories